What is good regulatory support for a start-up?

News

29 December 2024

1. Good support is not an option when creating a medical device

Creating an innovative medical device isn't just about developing a product that works. It also (and above all) means navigating a dense, technical and demanding regulatory environment.

MDR 2017/745 is a complex text. The expectations of notified bodies are high. And the pitfalls are numerous: technical documentation, clinical demonstration, PMS, risk management, classification, UDI, Eudamed... everything is intertwined. For a start-up, the slightest error in trajectory can cost months - or even the survival of the project.

In this context, regulatory support is not an "accessory" item. It's a strategic investment.

2. Regulatory support: strategic leverage from R&D onwards

An idea can be brilliant... but if it's poorly positioned from a regulatory point of view, it may never see the market. Conversely, intelligent support enables you toanticipate the right requirements, make the right design choices, and structure your project with a view to CE marking (or FDA).

Good regulatory advice right from the R&D phase helps to :

translate normative requirements into concrete technical criteria (design inputs, functionalities, safety, etc.),
anticipate risk class, classification rules and clinical impact (investigation or not? PMCF? etc.),
adapt the verification/validation strategy, taking into account the expected level of proof.

3. The ingredients of good regulatory support

A good regulatory consultant doesn't just recite the MDR. He or she must :

Be pedagogical: explain the texts without caricaturing them or making them more vague than they are.
Be pragmatic: adapt advice to the start-up's level of maturity (tech, clinical, financial).
See the big picture: connect the dots between R&D, risk management, clinical, quality and filing strategy.
Get involved: co-construct the trajectory, not just deliver documents.

In short, good support is as much about substance as it is about attitude. It's not about "doing things for", it's about "growing" the team's ability to understand, arbitrate and decide.

4. What CSDmed does

At CSDmed, we don't chase deliverables.

We work with start-ups that have a medical need, a technology or an intuition. And we help them structure a clear, realistic regulatory path, consistent with their means and ambition.

What makes the difference?

An integrated approach: regulatory, quality, clinical, R&D... everything is connected.
A partnering approach: no tunnel effect, we move forward together.
Adaptation to the context: split support as needed, depending on progress or funding.
An international vision: CE, FDA, UKRP, trustee... we're at ease in several fields.

5. Case studies

Case 1 - Avoiding a 6-month delay thanks to good anticipation

A cardiology start-up was planning a clinical study in France to validate its implantable DM. During our preliminary review, we identified a wrong choice of class (IIb instead of III), based on an incomplete interpretation of MDR rule 8.

As a result, without our intervention, the study would have been launched without the opinion of a notified body, rendering the clinical data unusable for CE marking.

We reviewed the strategy, contacted the NB beforehand, and enabled the start-up to get off to a solid start... and, above all, a valid one.

Case 2 - A strategic pivot to target Class I

A project leader had designed a post-operative wound monitoring software. His initial intuition: "It's got to be class IIa, it's got AI and image processing".

After a serious regulatory study, we demonstrated that the DM could, as it stood, be qualified as class I, under certain conditions. This regulatory pivot enabled us toaccelerate time-to-market by 12 to 15 months, avoiding the need to submit to an ON in the first instance. The product is now on the market, with a plan for gradual upgrading.

6. Mini FAQ

Does a start-up really need a regulatory consultant from the outset?

Yes, especially if you're developing an innovative product or one that doesn't fit neatly into the traditional regulatory framework. Good advice upstream avoids costly mistakes later on.

What are the risks of poor support?

Under-classification, inappropriate clinical strategy, non-conformity of design, poor technical documentation... The damage can be extensive and take a long time to correct.

When should CE marking be considered?

As early as the design phase. CE marking is not a final step, but a trajectory that begins with the first design choices.

Can you also provide FDA support?

Yes, at CSDmed we're at home on both continents. CE and FDA are not opposites: they coordinate with each other.

Is it possible to work in several stages, depending on funding?

Yes. We know how to adapt the pace and milestones to the maturity of the project, without sacrificing rigor.

7. Good support is a lever for agility, not a luxury

Properly understood and anticipated, regulations can accelerate your project. They force you to clarify, structure and prioritize.

At CSDmed, we support start-ups with seriousness, flexibility and commitment. We know the loneliness of the early days, the doubts, the financial trade-offs... and we know how to transform these constraints into solid trajectories.

Are you developing a medical device and need a partner to structure your regulatory process?

Write to us. We'll work with you to turn your ambitions into reality.